Clinical Trials List
2022-03-31 - 2027-12-31
Phase III
Not yet recruiting4
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 邱彥程 未分科
- Yih-Jyh Lin 未分科
- Hsin-Yu Kuo 未分科
- Ting-Tsung Chang 未分科
- Liu Yi-Sheng 未分科
- Chiu Hung Chiu 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- CHUNG-HSIN CHANG 未分科
- 劉嘯天 未分科
- Sheng-Shun Yang 未分科
- 蔡炘儒 無
- 張碧倚 無
- 呂宜達 未分科
- 鄭紹彬 未分科
- 廖苡君 未分科
- 賴家鈺 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
Co-Principal Investigator
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
725 participants
